JP2014518255A5 - - Google Patents

Download PDF

Info

Publication number
JP2014518255A5
JP2014518255A5 JP2014518000A JP2014518000A JP2014518255A5 JP 2014518255 A5 JP2014518255 A5 JP 2014518255A5 JP 2014518000 A JP2014518000 A JP 2014518000A JP 2014518000 A JP2014518000 A JP 2014518000A JP 2014518255 A5 JP2014518255 A5 JP 2014518255A5
Authority
JP
Japan
Prior art keywords
chloro
methoxyphenyl
dihydro
trifluoromethyl
fluoro
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2014518000A
Other languages
English (en)
Japanese (ja)
Other versions
JP6012726B2 (ja
JP2014518255A (ja
Filing date
Publication date
Priority claimed from EP11171532A external-priority patent/EP2540295A1/en
Application filed filed Critical
Publication of JP2014518255A publication Critical patent/JP2014518255A/ja
Publication of JP2014518255A5 publication Critical patent/JP2014518255A5/ja
Application granted granted Critical
Publication of JP6012726B2 publication Critical patent/JP6012726B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2014518000A 2011-06-27 2012-06-19 脆弱x症候群の治療用組成物 Active JP6012726B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP11171532.2 2011-06-27
EP11171532A EP2540295A1 (en) 2011-06-27 2011-06-27 Compositions for the treatment of Fragile X syndrome
PCT/IB2012/053089 WO2013001412A1 (en) 2011-06-27 2012-06-19 Compositions for the treatment of fragile x syndrome

Publications (3)

Publication Number Publication Date
JP2014518255A JP2014518255A (ja) 2014-07-28
JP2014518255A5 true JP2014518255A5 (cg-RX-API-DMAC7.html) 2015-07-16
JP6012726B2 JP6012726B2 (ja) 2016-10-25

Family

ID=44840530

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2014518000A Active JP6012726B2 (ja) 2011-06-27 2012-06-19 脆弱x症候群の治療用組成物

Country Status (8)

Country Link
US (1) US10435366B2 (cg-RX-API-DMAC7.html)
EP (2) EP2540295A1 (cg-RX-API-DMAC7.html)
JP (1) JP6012726B2 (cg-RX-API-DMAC7.html)
DK (1) DK2723336T3 (cg-RX-API-DMAC7.html)
ES (1) ES2797395T3 (cg-RX-API-DMAC7.html)
PL (1) PL2723336T3 (cg-RX-API-DMAC7.html)
PT (1) PT2723336T (cg-RX-API-DMAC7.html)
WO (1) WO2013001412A1 (cg-RX-API-DMAC7.html)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2540295A1 (en) * 2011-06-27 2013-01-02 Centre national de la recherche scientifique Compositions for the treatment of Fragile X syndrome
EP2967405A4 (en) * 2013-03-15 2017-01-11 The Children's Hospital of Philadelphia Magnetoencephalography biomarkers of gaba-b agonist drug activity in autism spectrum disorders
EP3256112A1 (en) 2015-02-13 2017-12-20 Canbex Therapeutics Limited Compounds for treating disorders associated with bk channel modulation
WO2018157046A1 (en) 2017-02-24 2018-08-30 Ovid Therapeutics Inc. Methods of treating seizure disorders
WO2019126643A1 (en) 2017-12-22 2019-06-27 Massachusetts Institute Of Technology Compositions and methods for williams syndrome (ws) therapy
EP3912625A1 (en) 2020-05-20 2021-11-24 Kaerus Bioscience Limited Novel maxi-k potassium channel openers for the treatment of fragile x associated disorders
WO2025233532A1 (en) 2024-05-10 2025-11-13 Les Laboratoires Servier Maxi-k potassium channel openers and therapeutic applications thereof

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5565483A (en) * 1995-06-07 1996-10-15 Bristol-Myers Squibb Company 3-substituted oxindole derivatives as potassium channel modulators
CA2425771A1 (en) 2000-10-13 2002-04-18 Christopher G. Boissard Selective maxi-k- potassium channel openers functional under conditions of high intracellular calcium concentration, methods and uses thereof
WO2002072088A2 (en) * 2001-02-20 2002-09-19 Bristol-Myers Squibb Company Modulators of kcnq potassium channels and use thereof in treating migraine and mechanistically related diseases
EP1363624A2 (en) * 2001-02-20 2003-11-26 Bristol-Myers Squibb Company Fluoro oxindole derivatives as modulators of kcnq potassium channels
FR2857452B1 (fr) * 2003-07-11 2005-09-30 Univ Rabelais Francois Test de depistage de l'autisme, methode de selection de patients repondant audit test et utilisation des medicaments activateurs de canaux bkca pour le traitement de ladite maladie
DE102004053673A1 (de) * 2004-11-03 2006-05-04 Endress + Hauser Flowtec Ag Vorrichtung zur Bestimmung und/oder Überwachung des Volumen- und/oder Massendurchflusses eines Mediums
US20100247552A1 (en) 2006-11-10 2010-09-30 Massachusetts Institute Of Technology Pak modulators
WO2009000038A1 (en) * 2007-06-28 2008-12-31 Cnsbio Pty Ltd Combination methods and compositions for treatment of neuropathic pain
EP2540295A1 (en) * 2011-06-27 2013-01-02 Centre national de la recherche scientifique Compositions for the treatment of Fragile X syndrome

Similar Documents

Publication Publication Date Title
JP2014518255A5 (cg-RX-API-DMAC7.html)
CL2013001316A1 (es) Composicion que comprende micro-organismo probioticos no replicantes que protegen contra las infecciones del tracto respiratorio superior.
EP2440210A4 (en) METHOD FOR THE TREATMENT OF STOMACH DARM DISEASES
CL2007003686A1 (es) Compuestos derivados de indol con anillo unido en las posiciones 4,5; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para tratar una infeccion viral.
IL210319A0 (en) Compounds and pharmaceutical compositions for the treatment of viral infections
CL2013001715A1 (es) Compuestos derivados de indol, inhibidores de la replicacion del rsv; procedimiento de preparacion; composicion farmaceutica; y su uso para el tratamiento de la infeccion por el virus sincicial respiratorio.
IL233677A (en) Benzysacazole Compounds Aminopyrazolo-Primidine Converted, Pharmaceuticals Containing Them, and Use of Drug Manufacturing Composition
WO2013123215A3 (en) Antiviral drugs for treatment of arenavirus infection
EA201001847A1 (ru) Соединения и композиции, применяемые для лечения малярии
WO2009114601A3 (en) Preparation of lenalidomide
WO2011113060A3 (en) Antiviral compounds and methods of use thereof
IL195272A0 (en) Methods and compositions for the treatment of viral infections
EP2496251A4 (en) METHOD, COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT AND PROPHYLAXIS OF RESPIRATORY DISEASES
CL2012003523A1 (es) Método para la preparación de una composición farmacéutica que contiene un portador de oxígeno termoestable; composicion farmaceutica que contiene un portador de oxigeno altamente purificado y termoestable.
HK1201477A1 (en) Pharmaceutical composition of omeprazole
WO2013022550A3 (en) Small molecule inhibitors of ebola and lassa fever viruses
CL2016000300A1 (es) Métodos terapéuticos
CN302152011S (zh) 包装罐(1)
CN302339401S (zh) 瓶子(天工臻赏)
CN302044245S (zh) 笔夹(楼梯形)
CN302028212S (zh) 酒瓶(201201)
CN302082376S (zh) 喷头(三层次反射喷头)
CN302400661S (zh) 燃气炉外火盖(hs078a)
CN302311201S (zh) Led封装单元(0909)
CN302173455S (zh) 玻璃包装瓶(花椒油)